ISSN 1443-850X

In this edition....
Coverage from the 20th Bioshares Biotech Summit..

Companies covered: BB1, CGS, CU6, NEU, TLX

BIOSHARES

Australia's Independent Biotech Investment Resource, est.1999

21 August 2026
Edition 998

Bioshares Biotech Summit Coverage

Clarity Pharmaceuticals Aims for 2028 Launch as Direct Competition to Illuccix and Pylarify Products

Clarity Pharmaceuticals (CU6: $2.48) Executive Chairperson Alan Taylor wants its first radioisotope product to be one of the few billion dollar success stories to come from Australian discoveries (joining Gardasil from the University of Queensland, Venclexta from WEHI, Relenza from Monash/ANU/CSIRO and Ojjaaro from the Ludwig Institute for Cancer Research in Melbourne developed discovered by Andrew Wilks and Chris Burns (now CEO of Amplia Therapeutics)).

Built in collaboration with the University of Melbourne, Clarity's lead product is a diagnostic for prostate cancer, SAR-bisPSMA, which the company is seeking to position as the next generation, improved version of existing products such as Illuccix (^{68}Ga-PSMA-11 from Telix Pharmaceuticals) and Pylarify (from Lantheus Holdings, currently being acquired by Cerium for US$8 billion).

Continued over

Neuren Pharmaceuticals - DAYBUE Sales Growth Stuns Market

Neuren Pharmaceuticals (NEU: $22.46) has seen its share price surge on unexpected strong sales growth in DAYBUE, the therapy developed initially by Neuren and subsequently licensed to its partner Acadia Pharmaceuticals for the treatment of Rett syndrome.

DAYBUE sales jumped by 30% in the June quarter over the PCP to US$125 million, the highest quarterly sales recorded. For the quarter Neuren will receive royalties of US$12.9 million.

By comparison, sales in the June quarter 2025 increased by just 13% over the PCP. And sales in the March quarter this year fell by 8% to US$101 million, which appears to be a seasonal dynamic.

Continued on page 5

BlinkLab Delivers Very Good Results in Second Indication, ADHD

Smartphone-based neurobehavioral diagnostic company BlinkLab (BB1: $0.885) has delivered some very good results in the second application of the company's technology, in assessing ADHD in children.

In the first exploratory study against a healthy control arm in 208 subjects in total, the company's technology achieved a sensitivity in the positive arm of 82% and correctly assessing the control arm subjects in 83% of cases (specificity). This is likely as accurate as the test can achieve given the often discordant results that can often be arrived at by two specialists (i.e. the gold standard).

Continued on page 6

	Bioshares Portfolio
Year 1 (May '01 - May '02)	21.2%
Year 2 (May '02 - May '03)	-9.4%
Year 3 (May '03 - May '04)	70.6%
Year 4 (May '04 - May '05)	-16.3%
Year 5 (May '05 - May '06)	77.8%
Year 6 (May '06 - May '07)	17.4%
Year 7 (May '07 - May '08)	-35.8%
Year 8 (May '08 - May '09)	-7.4%
Year 9 (May '09 - May '10)	50.2%
Year 10 (May '10 - May'11)	45.4%
Year 11 (May '11 - May '12)	-18.0%
Year 12 (May '12 - May '13)	3.1%
Year 13 (May '13 - May '14)	26.6%
Year 14 (May '14 - May '15)	23.0%
Year 15 (May '15 - May '16)	33.0%
Year 16 (May '16 - May '17)	16.8%
Year 17 (May '17 - May '18)	-7.1%
Year 18 (May '18 - May '19)	-2.3%
Year 19 (May '19 - May '20)	39.5%
Year 20 (May '20 - May '21)	86.8%
Year 21 (May '21 - May '22)	-15.6%
Year 22 (May '22 - Dec '22)	-2.2%
Year 23 (CY2023)	-15.4%
Year 24 (CY2024)	40.8%
Year 25 (CY2025)	20.3%
Year 26 (CY2026 - current)	-17.2%
Av. Annual gain (25 yrs)	17.7%

Bioshares is published by Blake Industry & Market Analysis Pty Ltd. ACN 085 334 292
AFS Licence No. 258032

Mark Pachacz – Editor/Analyst
Email: Bioshares1[at]gmail.com
Ph: 0403-850-425

Edition Number 998 (21 August 2026)

– Clarity cont'd from page 1

Aside from the isotope used by Clarity (Copper-64), the key difference to the incumbent products is that it has two PSMA binding sites (rather than one), and is enclosed in a cage (chelator) to hold the isotope.

Clarity has three Fast Track Designations (FTDs) for this product. These are for use prior to prostate cancer surgery (to image the tumour and identify any tumour spread), in biochemical recurrence (when the cancer has spread from the original site) and also for the therapy using the same binding compound but a stronger isotope to ablate the tumour (copper-67).

Talyor stressed that FTDs are given to products for which there is a high unmet need, even though there are three diagnostic products on market for prostate cancer imaging and one therapeutic.

The diagnostic space is dominated by Telix Pharmaceuticals and Lantheus Holdings generating revenue of around US$2 billion a year. However the products in current use have very short half-lives said Taylor (between 1-2 hours). Taylor acknowledged the feat that has been achieved by these companies in supplying the tests across the US when working with products with such short half-lives. By comparison Clarity's isotope has a half-life of 12.7 hours.

The imaging window for the incumbent products is between 50 - 100 minutes, compared to up to 30 hours for Clarity's SAR-bisPSMA. And all of the products on the market are monomers with single binding to PSMA. Taylor said that this contributes to poor sensitivity. The specificity is excellent but the sensitivity is 'incredibly poor' (between 27% to 40%).

The sensitivity and specificity of Clarity's prostate cancer imaging agent will be released early next year from the company's Phase III studies (AMPLIFY and CLARIFY in patients with biochemical recurrence and in patients prior to surgery).

All of Clarity's studies have been head-to-head comparisons with the current products on market, including preclinical and clinical studies. Using the dimer binding action, there is greater binding to the cell surface and more of the product is internalized by the cell compared to monomer products.

So far Clarity has imaged over 750 patients and performed more than 1,500 scans with its test.

Study Results - Pre-Surgery (Phase I and Phase III underway)

The first clinical trial Clarity conducted was a Phase I study called PROPELLAR in 30 patients (before surgery), comparing Clarity's agent with ^{68}Ga-PSMA-11. The Clarity diagnostic achieved 2-3 times as much tumour uptake of the isotope, as well as picking up lesions not identified with the ^{68}Ga-PSMA-11 with same day imaging.

The Clarity test picked up 29% more lesions in the same patients with a favourable tolerability profile with just one Grade 1 adverse event.

From that trial the company moved into its CLARIFY study in 383 patients which is expected to shortly complete recruitment. Results are expected early next year. Sensitivity and specificity will be the primary endpoint, with Talyor hoping that Clarity will be the first company to successfully meet the PSMA imaging endpoint. The secondary endpoint will be comparisons with existing PSMA imaging products where patients have been previously imaged with those agents. One difference from the Phase I study will be imaging on the same day, as well as taking a second image on Day 2.

BCR Studies (past and Phase III underway)

Imaging biochemical recurrence of prostate cancer is the largest market said Taylor. The company is currently conducting a Phase III study (AMPLIFY) in this patient population, with results also expected early next year. The Phase III AMPLIFY study has enrolled 232 patients with very strong interest in the study from clinics according to Taylor and limited to 30 patients per site.

A Phase I/II study (COBRA) has been conducted in 50 patients. A key difference from the PROPELLAR study was that this trial looked at not just same day, but also next day imaging. Taylor said that many patients who entered this study had a negative result from current PSMA imaging products (either the Gallium-68 based product or Pylarify which uses fluorine-18).

Results from this study showed 82% more lesions when measured the next day compared to Day 1 (both with the Clarity imaging agent). In terms of patients reading negative on Day 1, 34% more of patients imaged on Day 2 were diagnosed with a positive result using the Clarity test. What is astounding is how much more isotope is absorbed and washed out of surrounding benign tissue by waiting an additional 24 hours, with a five fold increase in what is termed "tumour-to-background ratio."

Taylor said that what was particularly impressive is that the Clarity test picked up lesions not detected by other PSMA products (Illuccix and Pylarify) six months later. (53 lesions detected using the Clarity test compared to just 20 lesions detected six months later using current PSMA approved products).

Co-PSMA Study (direct comparison with ^{68}Ga-PSMA-11)

The Co-PSMA study was an investigator-initiated trial involving 50 patients. It was designed to directly compare the Clarity diagnostic with the ^{68}Ga-PSMA-11 test, with patients receiving both tests within a three week period. Taylor stressed that the lesions were not expected to growth in the three weeks between the tests.

Taylor said that the data was 'incredible'. On average there were 2.6 times more lesions detected using the Clarity test compared to the ^{68}Ga-PSMA-11 test. Of the subjects, 11 additional patients were detected (imaged) with prostate cancer using the Clarity test where the 68Ga-PSMA-11 (Illuccix) did not register as a positive scan. Taylor stressed that this study involved the same patients and same camera in each case.

Continued over

– Clarity cont'd from previous page

The results also had a decisive impact on how the patients were managed. Following the ^{68}Ga-PSMA-11 test, 66% were recommended active treatment, however this increased to 90% of patients following imaging with the Clarity test. The Co-PSMA results were presented and published in March this year.

Compassionate Use Data

In a compassionate use program, 10 patients who received a negative result with ^{68}Ga-PSMA-11 were imaged using the Clarity test. Eight of these patients were imaged as positive using the Clarity test with a change of treatment in all eight patients, including four undergoing targeted radiotherapy. The two who were negative with the Clarity test had very low PSA blood levels.

Even when using the hi-tech Siemens Biograph Vision Quadra imaging machine, lesions were detected in all five patients with a negative ^{68}Ga-PSMA-11 or Pylarify scan resulting in changed therapy management for all five patients. Day 2 imaging detected twice as many images compared to those identified on Day 1.

Taylor finished with claims made by competitors which limit the Clarity technology, which Taylor strongly disagrees with. The responses to each point from Clarity are provided on the ASX presentation from the company.

Responding to a question around the recent acquisition of Lantheus by Cerium for US$8 billion, Taylor believes consolidation is a positive for the sector, with the company more closely aligned with the leader in the field, Novartis, in terms of technology fit.

Taylor complimented Telix on the rollout of a one hour half-life product, which is incredibly difficult, with generators required near patients. By comparison however, the Clarity isotope has a 12.7 hour half-life, which also allows next day imaging. Clarity is seeking to go head-to-head in the market in 2028 against Illuccix and Pularify.

On the topic of safety, the diagnostic is low dose. In the higher dose therapy, only two patients (from 35) have registered Grade III haematology toxicity issues (no Grade IV side effects) with 31% of patients achieving complete responses (undetectably disease) and more than a 75% drop in PSA levels in more than half of the patients. "That's a phenomenal safety profile for a therapy, let alone the responses," said Taylor.

Clarity Pharmaceuticals is capitalized at $925 million with $178 million in cash at the end of June.

Bioshares recommendation: **Speculative Buy Class A**

The stock has been added to the Bioshares Model Portfolio.

Bioshares Biotech Summit Coverage

Telix Pharmaceuticals - "Therapeutics are Going to Generate the Future Revenue"

Mike Wheatcroft, head of R&D at Telix Pharmaceuticals (TLX: $15.62), delivered a scientific viewpoint of the company's progress and programs, particularly around prostate cancer screening and treatment. Wheatcroft has been at Telix from the beginning when it was just three people and has been involved with most programs.

Wheatcroft said that the mission of Telix is to develop a high value therapeutics pipeline. *(Whilst the prostate cancer imaging agents Illuccix and Pylarify are generating sales of around US$2 billion, the therapeutic, Pluvicto from Novartis, is tracking sales at US$2.6 billion with peak sales expected to reach US$5 billion).*

A major asset for Telix is its vertically integrated manufacturing and supply chain. Wheatcroft said that even Novartis has struggled to supply its product which has a time sensitive profile. The reason that Telix can deliver its product with such a short half-life is because it controls the supply chain.

Whilst not directly addressing the looming competition from Clarity Pharmaceuticals in the diagnostic space, a feature of Telix's growth platform is to explore new molecular entities to improve safety and efficacy. The company is not tied to the use of one targeting agent or one isotope. This includes gaining access to 'minibodies' in January last year from ImaginAb. These minibodies can potentially allow faster penetration into the tumours as well as faster clearance from the body. Wheatcroft said the company is seeking to move these new antibody-based radiotherapies into the clinical towards the end of this year.

It has also acquired Artemis to ensure consistency of product produced in cyclotrons.

Three Priorities for 2026

Telix has three strategic priorities for this year. The first is to continue to grow sales from its Precision Medicine Business (Illuccix and the next generation product Gozellix) which funds the therapeutics R&D programs. Sales from these products in the first six months of 2026 were US$388 million (up 27%) with EBITDA from this business up 26% to US$132 million. Wheatcroft said that this market continues to expand. Over the full year the company is expecting over US$1 billion in revenue, including US$40 million received from the recent Regeneron partnership signed.

Continued over

– Telix cont'd from previous page

The second priority is to launch the brain imaging agents, Pixclara and Pixlumi in the US and Europe respectively, with approval submissions having been accepted for review in both territories. An approval decision from the FDA is expected by 11 September. And Zircaix (for liver cancer imaging), which Wheatcroft said had some setbacks last year, is very close to resubmission for approval with the FDA.

The third key area is in advancing the company's therapeutic pipeline. The company now has three Phase III programs underway in therapeutic applications, these being in prostate cancer (with FDA alignment received last month to proceed with the Phase III program in the US) and the first patients enrolled in the Phase II/III recurrent glioblastoma and kidney cancer treatment studies. Wheatcroft said the FDA has accepted that its proposed prostate cancer (mCRPC) therapy trial involves a safe and tolerable dose of TLX591-Tx.

(The Prostate cancer study will seek to recruit 520 patients with a primary completion date at the end of next year. The glioblastoma study is looking to recruit 50 patients with a primary completion date of July next year. And the kidney cancer therapy study is seeking to recruit 40 patients with a primary completion date of August next year.)

Wheatcroft said that recurrent glioblastoma is a very tough disease to treat, although remains optimistic with a median overall survival of 32 months in a Phase II study which Wheatcroft said is "pretty amazing."

"We have a lot of hope for this asset to be able to change patient lives."

Multiple Products for Similar Indications

In the prostate cancer therapy setting, in additional to the lead compound TLX591-Tx (an antibody), the company is also developing TLX597-Tx (a small molecule) which Wheatcroft said was similar in structure to Pluvicto and the therapeutic being developed by Clarity Pharmaceuticals. What is different about this potential therapy (to Pluvicto) is that it has a very high uptake in tumours in both bone and soft tissue – more than double that with Pluvicto – without affecting the salivary glands and kidneys. This therapy is being positioned to go head-to-head against Pluvicto in hormone-sensitive prostate cancer (which gained approval for that indication last month).

Telix is also developing an alpha-emitter (TLX592-Tx) for the treatment of prostate cancer which delivers a more potent payload using an engineered antibody that clears very quickly from the blood. This is required where patients develop resistance to radiotherapy.

Alpha particles are 7,000 times heavier than beta particles, have a higher energy and also function in a more localised manner as they have shorter penetration into tissue. This makes it easier to control the delivery of the radiation and potentially fewer adverse events said Wheatcroft. They are also more commercially friendly for delivery said Wheatcroft with not as much shielding required.

The other alpha emitter being developed is TLX252-Tx including for the treatment of kidney cancer.

Both alpha emitter studies are expected to start this year with ethics approval received. Access to the alpha emitting isotopes can be more difficult, although Telix has secured access to Pb^{212} and Ac^{225}.

The company is also developing a radiotherapy for metastatic bone cancers for palliative care (TLX090-Tx).

BiPASS Study Could Double Market for Illuccix and Gozellix

In the diagnostic area, Telix is seeking to expand the market for Illuccix and Gozellix, conducting the BiPASS study. The biopsy process for early stage prostate cancer is highly invasive, with 75% being negative and high risk. Expanding into early imaging would double the market for Illuccix and Gozellix said Wheatcroft.

Patients which suspicion of prostate cancer (from a previous MRI scan or from a recommendation from their specialist) can enroll in the study which will use MRI and Illuccix to potentially rule out the need for a biopsy. The study will seek to enroll 338 patients (with enrolment almost complete) and results towards the end of this year.

Melbourne Innovation Centre Opened

Telix's manufacturing responsibilities are housed in its TMS (Telix Manufacturing Solutions) division, which produces radioisotope products for drug discovery, translational medicine, clinical studies and for commercial use. "It is so critical to have your own infrastructure. It's a sign of a mature radiopharma industry that you have all of the pieces of the puzzle to supply doses to patients reliably and reproducibly," said Wheatcroft.

Telix recently opened its first clinical innovation centre in Australia with the TMS business unit. That facility can facilitate radiopharmaceutical production, and assess 'hot blood' from patients, a capability that not all hospitals have. Another floor is dedicated to patient dosing and patient imaging. And the top floor is a research lab and office space.

Summary

"The therapeutics are going to generate the future revenue, the future growth of the company," said Wheatcroft, whilst maintaining a commitment to the precision medicine (imaging) business.

Bioshares recommendation: **Speculative Buy Class A**

Bioshares

'Landmark Year' for Cogstate

Cogstate CEO Brad O'Connor said that it has been a landmark year for the company (CGS: $3.10). The company has been able to diversify away from its reliance on the field of Alzheimer's disease (accounting for just 14% of revenue) and has been able to expand the quantity of work through its channel partners.

In a strategy that was put in place five years ago, O'Connor said that it is now bearing fruit.

Sales (contracts signed) for the year were US$89 million which was up 116% on the PCP. Forty percent of this came from the company's channel partners, including its largest partner Medidata. This compares to just US$1 million of sales from channel partners in FY2025.

The partnership with Medidata, signed in October 2024, has taken some time to develop, with Medidata making up half of the channel partner revenue.

The investment of expansion into other areas such as mood/sleep/other neurology, and in rare diseases is now paying off, representing 46% and 33% of new contracts signed respectively in FY2026. Whilst the level of revenue from Alzheimer's disease is lower, the company remains very optimistic of the future revenue potential from this area of drug development.

The company is currently managing 171 studies for its pharmaceutical and biotech customers, up from 110 a year ago. Its gross profit margin for the year was 58%, which is expected to grow with revenue. O'Connor said the business has reached a position where there is "exceptional leverage over operating costs" as revenue grows.

The group revenue for the year was US$60.9 million with a profit before tax of US$16.1 million and profit after tax of US$11.9 million. The company will pay a $0.04 dividend, with a cash balance at the end of June of US$34.8 million.

Outlook

For the year ahead, Cogstate has US$46.1 million of revenue secured for this year from its clinical trials business, and US$29.1 million of revenue booked for FY2028. Based on the performance last year, Bioshares estimates revenue of US$80 million for this year, if similar levels of sales contracts can be signed. The company continues to see high levels of sales opportunities. O'Connor said that the FY2026 results are "just the start for our business."

Bioshares recommendation: **Hold**

Bioshares

– Neuren cont'd from page 1

If sales in North America exceed US$500 million in a calendar year, then Neuren will receive an additional US$50 million milestone payment, and a US$100 million milestone payment if sales pass US$750 million in a calendar year.

A driver of the sales growth has been a new formulation of the product, called STIX, which is a powder formulation that can be added to any drink (other than dairy). The new formulation was released in just April and by the end of June 40% of patients were using the STIX formulation, which CEO Jon Pilcher said is an incredibly quick switch. The new formulation was developed by Acadia. Many patients who discontinued the original formulation are now also returning to try the new STIX formulation according to Pilcher.

Acadia has increased its guidance by US$20 million for 2026 sales to between US$480 - US$510 million. Whilst adoption within the Centres of Excellence for Rett syndrome has been high at 60%, in other areas, including regional clinics, the take up has only been 28% which leaves "huge scope for growth" believes Pilcher.

Other milestones ahead include launch of the product in Europe, pending approval, with sales expected to begin in Germany in the December quarter. This will trigger a US$35 million milestone payment plus royalties from mid teens to just over 20% that are higher than the US. The CHMP overturned its original decision in Europe in June, with considerable input from the Rett community following an earlier negative CHMP view.

A trial in Rett syndrome is underway in Japan, with results due this year and an new drug application expected to be filed next year. Upon first commercial sale in Japan Neuren will receive a US$15 million milestone payment from Acadia plus royalties similar to Europe.

Neuren finished March with $293 million in cash, having received $543 million from Acadia for DAYBUE, with the product launched only in 2023.

Bioshares recommendation: **Hold**

Bioshares

Bioshares Model Portfolio (21 August 2026)

Company	Code	Price (current)	Price added to portfolio	Recommendation	Cap'n ($M)	Date added
Telix Pharmaceticals	TLX	$15.62	$7.85	Spec Buy A	$5,290	December 2021
Neuren Pharmaceuticals	NEU	$22.46	$3.25	Hold	$2,841	December 2021
PYC Therapeutics	PYC	$2.07	$1.03	Spec Hold A	$2,035	April 2025
Anteris Technologies	AVR	$12.63	$21.50	Spec Buy A	$1,250	September 2022
Clarity Pharmaceuticals	CU6	$2.48	$2.48	Spec Buy A	$925	August 2026
Cogstate	CGS	$3.10	$0.24	Hold	$530	April 2019
Clinuvel Pharmaceuticals	CUV	$10.42	$20.31	Buy	$522	November 2020
Aroa Biosurgery	ARX	$0.57	$1.11	Buy	$197	November 2021
Dimerix#	DXB	$0.310	$0.09	Spec Buy A	$186	December 2018
Actinogen Medical	ACW	$0.046	$0.04	Spec Buy B	$165	Feb 2026
Blinklab	BB1	$0.885	$0.855	Spec Buy A	$135	January 2026
Amplia Therapeutics	ATX	$0.150	$0.061	Spec Buy A	$77	April 2024
Cyclopharm	CYC	$0.495	$2.87	Spec Hold A	$60	October 2023
Botanix Pharmaceuticals	BOT	$0.020	$0.17	Spec Hold B	$54	July 2025
Syntara	SNT	$0.026	$0.26	Spec Buy A	$50	December 2016
Clever Culture Systems	CC5	$0.015	$0.09	Spec Buy A	$33	April 2022
Acrux	ACR	$0.010	$0.01	Spec Buy C	$5	June 2026

IN:
CU6 (See page 1)

OUT:
None

– BlinkLab cont'd from page 1

"Diagnosis (of ADHD) is a subjective clinical judgement, and two experienced clinicians assessing the same child often disagree," according to BlinkLab CEO Henk-Jan Boele. "Every test is therefore graded against a benchmark that carries its own error. Seen that way, BlinkLab's 82% sensitivity and 83% specificity sit close to the practical ceiling for any test scored against subjective clinical opinion."

The study was conducted across Mental Care Group clinics in the Netherlands. Two of the key benefits to the BlinkLab technology is that it can deliver an objective assessment, as well as substantially reduce the bottlenecks in clinical diagnosis of neurobehavioral disorders in children. CEO of the Mental Care Group said that the group "eagerly look forward to implementing BlinkLab into our diagnostic workflow."

The BlinkLab technology is being positioned as a tool to be used by clinicians to improve the diagnostic process of ADHD and autism in children and adults. A registration study in pediatric autism is currently underway in the US at 10 sites, with results due by the end of this year.

The company has nine other studies underway, with results due from a further four studies this year expected in adult autism (two studies), early dementia detection, and as a tool for use by pharma in treatment with ketamine (monitoring response to treatment).

In ADHD, the company plans to conduct a pilot study in the US as a precursor to an FDA registrational study in pediatric ADHD.

BlinkLab is capitalised at $135 million, after raising $17.5 million last quarter at $0.65 per share.

Bioshares recommendation: **Speculative Buy Class A**

Bioshares

How Bioshares Rates Stocks

For the purpose of valuation, Bioshares divides biotech stocks into two categories. The first group are stocks with existing positive cash flows or close to producing positive cash flows. The second group are stocks without near term positive cash flows, history of losses, or at early stages of commercialisation. In this second group, which are essentially speculative propositions, Bioshares grades them according to relative risk within that group, to better reflect the very large spread of risk within those stocks. For both groups, the rating "Take Some Profits" means that investors may re-weight their holding by selling between 25%-75% of a stock.

Group A

Stocks with existing positive cash flows or close to producing positive cash flows.

Buy	CMP is 20% < Fair Value
Accumulate	CMP is 10% < Fair Value
Hold	Value = CMP
Lighten	CMP is 10% > Fair Value
Sell	CMP is 20% > Fair Value

(CMP–Current Market Price)

Group B

Stocks without near term positive cash flows, history of losses, or at early stages of commercialisation.

Speculative Buy – Class A
These stocks will have more than one technology, product or investment in development, with perhaps those same technologies offering multiple opportunities. These features, coupled to the presence of alliances, partnerships and scientific advisory boards, indicate the stock is relative less risky than other biotech stocks.

Speculative Buy – Class B
These stocks may have more than one product or opportunity, and may even be close to market. However, they are likely to be lacking in several key areas. For example, their cash position is weak, or management or board may need strengthening.

Speculative Buy – Class C
These stocks generally have one product in development and lack many external validation features.

Speculative Hold – Class A or B or C

Sell

Corporate Subscribers: Cogstate, Syntara Dimerix, Imugene, Chimeric Therapeutics, Neuren Pharmaceuticals, Aroa Biosurgery, Clinuvel Pharmaceuticals, Clever Culture Systems, Actinogen Medical, Cynata Therapeutics, Acrux

Subscription Rates (inc. GST)

20 issues per year (electronic distribution): **$550**

For multiple email distributions within the same business cost centre, our pricing structure is as follows:	$900	2-3 email addresses
	$1200	4-5 email addresses
	$1500	6-10 email addresses

To subscribe, email this subscription form to: **bioshares1@gmal.com**

I enclose a cheque for **$** made payable to **Blake Industry & Market Analysis Pty Ltd**, or

Please charge my credit card **$** MasterCard ☐ Visa ☐

Card Number ☐☐☐☐ ☐☐☐☐ ☐☐☐☐ ☐☐☐☐

Signature _____ Expiry date _____

Subscriber details

Name _____

Organisation _____

Ph ( ) _____

Emails _____

_____

The information provided in Bioshares, including general investment advice, is provided only for receipt and use in Australia and New Zealand, for subscribers to Bioshares, who are Australian or New Zealand citizens or commercial entities.